logo Bio Valys Pharma
15 January 2026

Bio Valys Pharma is live!

Bio Valys Pharma announces official opening Bio Valys Pharma (BVP), a newly established pharmaceutical company, marks its official market entry with its medicine ESKESIA®, effective January 1, 2026.

As a subsidiary of International Drug Development (IDD), BVP strengthens the group’s capabilities by adding a dedicated pharmaceutical exploitation and commercial platform to IDD’s renowned expertise in development and regulatory consulting.
Together, the group delivers a seamless, end-to-end solution to support your product’s journey to market.
Headquartered in Paris, BVP is a European-based company led by a team of seasoned professionals with over 30 years of experience in the pharmaceutical industry.

Press release dated January the 6th, 2026

Linkedin post

IDD+BVP
04 September 2025

IDD launches new Website to enhance client experience and showcase expertise

IDD, a leading consulting firm specializing in regulatory affairs and development strategy for the pharmaceutical industry, today announced the launch of its newly redesigned website. The new site offers a user-friendly experience with improved navigation and functionality, allowing visitors to easily access detailed information about the company's comprehensive services.

The redesigned website reflects IDD’s commitment to providing high-end, tailored solutions across the entire drug value chain. Key features of the new site include:

  • In-depth service descriptions: A clear overview of IDD’s core services, including asset pre-approval, medicines post-approval, and business platform services.
  • Streamlined navigation: An intuitive design that makes it easy for visitors to find the information they need.
  • Modern and responsive design: A seamless experience across all devices.

“We are thrilled to launch our new website and provide our clients and partners with a more engaging and informative online experience,”.

“This new site is a testament to our ongoing commitment to excellence and innovation in the pharmaceutical consulting industry.”

The new website will be regularly updated with news, insights, and company updates. Visitors are encouraged to explore the site and learn more about IDD’s services.

25 July 2025

The IDD and Biovalys teams are growing again!

Since the arrival of Anne Walter and Stéphane Simon earlier this year, International Drug Development and BioValys Pharma have welcomed three new team members with diverse and valuable backgrounds.

First, Clarisse Ribeiro, who joined in MM/2025, holds a degree in [to be completed], and specializes in [to be completed].

Next, Mohamed ALILI, a Doctor of Pharmacy since 2020 in Algeria, is currently completing an internship to validate his degree in France. He is involved in Quality Assurance and Regulatory Affairs under the direct supervision of Anne Walter.

Finally, we welcomed a second intern in May 2025. Swann Walch is completing his fifth-year pharmacy internship under the supervision of Stéphane Simon, contributing to business development and the integration of AI into company processes.

These new additions reflect the energy and momentum of both companies, their appeal to young talent, and their commitment to excellence, innovation, and knowledge sharing.

18 June 2025

Team Seminar: Heading to 2030

A day driven by collaboration, creativity, and commitment. Together, we shaped our collective identity and set bold ambitions for the years ahead.
Our team is a true mosaic of expertise—diverse, agile, and united by a shared purpose. With energy and boldness, we aim to be a catalyst for success, empowering our clients to thrive in a fast-changing world.
26 May 2025

Who are we? – Episode 2

Meet the IDD crew: a multidisciplinary team of experts in development, regulatory strategy, industrial affairs, business operations, and exploitation. Agile, experienced, and fully committed to delivering tailored solutions across the entire pharmaceutical value chain.
18 March 2025

Who are we? – Episode 1

Our leadership team brings over 30 years of experience across the pharmaceutical value chain—from early development to commercialization. United by a shared commitment to execution and impact, we’ve completed over 3,000 missions to advance health.
07 March 2025

What do we do? – Episode 3

In the final chapter of our three-part series, we present our pharmaceutical business platform and exploitant services, designed to support commercial operations, regulatory compliance, and strategic market access.
27 February 2025

What do we do? – Episode 2

In this second chapter of our three-part series, we explore our post-approval expertise, including regulatory affairs, life-cycle management, and strategic support for marketed medicines.
19 February 2025

What do we do ?

This is the first episode in a three-part series introducing the core activities of International Drug Development (IDD). In this first chapter, we focus on our pre-approval expertise and strategic support for asset development.
13 January 2025

Happy New Year 2025!

As we begin this new year, the entire team at International Drug Development (IDD) extends its warmest wishes for happiness, health, and success in 2025.

2024 ended on a high note with the celebration of IDD’s 20th anniversary alongside our valued partners and clients. This milestone was made possible thanks to the dedication and expertise of our team members, the true driving force behind our achievements.

In 2025, we look forward to continuing our collaboration on your development plans, regulatory challenges, and business operations. May this year bring fruitful partnerships, growth, and exciting new opportunities.